Abstracts Archive - Page 1279 of 2425 - ACR Meeting Abstracts

Abstract Number: 1102 • 2017 ACR/ARHP Annual Meeting
Choosing Unwisely: HLA-B27 Testing and Adherence to Choosing Wisely Practices in a Large Integrated Academic Healthcare System
Marc W. Nolan^1,2, Morgan M. Brown³ and Elie Gertner^1,2, ¹Section of Rheumatology, Regions Hospital, St. Paul, MN, ²Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ³HealthPartners Institute, St. Paul, MN
Background/Purpose: The ACR in 2013 and the Canadian Rheumatology Association (CRA) in 2015 published their respective Choosing Wisely recommendations to promote evidence-based care and reduce…
Abstract Number: 1103 • 2017 ACR/ARHP Annual Meeting
Towards Recommendations on Functional Assessment Status Measures for Rheumatoid Arthritis: Preliminary Results from a Systematic Review
Claire Barber¹, JoAnn Zell², Jinoos Yazdany³, Aileen Davis⁴, Linda S. Ehrlich-Jones⁵, Carter Thorne⁶, Donna Everix⁷, Laura Cappelli⁸ and Kaleb Michaud⁹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²National Jewish Medical Center, Denver, CO, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Health Care and Outcomes Rsrch, Toronto Western Research Institute, University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Rehabilitation Institute Chicago, Chicago, IL, ⁶Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁷OnMyCare Home Health, Fremont, CA, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank for Rheumatic Diseases, Omaha, NE
Background/Purpose: Functional status assessment measures (FSAMs) are important outcomes in rheumatology and used to monitor response to treatment and aid in prediction of rheumatic disease…
Abstract Number: 1104 • 2017 ACR/ARHP Annual Meeting
A Genome-Wide Association Study of Gout in People of European Ancestry
Tony R. Merriman¹, Murray Cadzow¹, Marilyn E. Merriman¹, Amanda Phipps-Green¹, Ruth Topless¹, Abhishek Abhishek², Mariano Andrés³, Linda A. Bradbury⁴, Russell Buchanan⁵, Katie Cremin⁶, Erika De Guzman⁶, Janak de Zoysa⁷, Michael Doherty⁸, Catherine Hill⁹, Tom W.J. Huizinga¹⁰, Tim Jansen¹¹, M. Janssen¹², Leo .A.B. Joosten¹³, Fina Kurreeman¹⁴, Susan Lester¹⁵, Frederic Liote¹⁶, Donia Macartney-Coxson¹⁷, Hirotaka Matsuo¹⁸, Geraldine M. McCarthy¹⁹, Sally McCormick²⁰, Rinki Murphy²¹, Karel Pavelka²², Fernando Perez-Ruiz²³, Juan Puig²⁴, Timothy RDJ Radstake²⁵, Philip Riches²⁶, Maureen Rischmueller²⁷, Edward Roddy²⁸, Malcolm Smith²⁹, Eli A. Stahl³⁰, Blanka Stiburkova³¹, Richard Stubbs³², Anne-Kathrin Tausche³³, Rosa Torres³⁴, Rob Walker¹, Ken Yamamoto³⁵, Matthew A. Brown⁶, Hyon K. Choi³⁶, Nicola Dalbeth²¹, Jeffrey N. Miner³⁷, Alexander So³⁸, Lisa K. Stamp³⁹ and Tanya Major⁴⁰, ¹University of Otago, Dunedin, New Zealand, ²Devision of Rheumatology, University of Nottingham, NG5 1PB, England, ³Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ⁴Queensland University of Technology, Brisbane, Australia, ⁵University of Melbourne, Melbourne, Australia, ⁶Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁷Waitemata District Health Board, Auckland, New Zealand, ⁸Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁹Medicine, The University of Adelaide, Adelaide, Australia, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹¹VieCuri Medical Center, Venlo, Netherlands, ¹²Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, ¹³Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, ¹⁵Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ¹⁶University Paris Diderot, Paris, France, ¹⁷Institute if Environmental and Scientific Reseacrh, Wellington, New Zealand, ¹⁸Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ¹⁹Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ²⁰Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²¹University of Auckland, Auckland, New Zealand, ²²Institute of Rheumatology, Prague, Czech Republic, ²³BioCruces Health Research Institute, Barakaldo, Spain, ²⁴Hospital Universitario La Paz, Madrid, Spain, ²⁵Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²⁶University of Edinburgh, Edinburgh, United Kingdom, ²⁷Rheumatology, The Queen Elizabeth Hospital, South Australia, Adelaide, Australia, ²⁸Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²⁹Flinders Medical Centre and Repatriation Hospital, Adelaide, Australia, ³⁰Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ³¹Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³²P3 Research Limited, Wellington, New Zealand, ³³Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ³⁴La Paz University Hospital, Madrid, Spain, ³⁵Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³⁷Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³⁸Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, ³⁹University of Otago, Christchurch, New Zealand, ⁴⁰Biochemistry, University of Otago, Dunedin, New Zealand
A genome-wide association study of gout in people of European ancestryBackground/Purpose: Genome wide association studies (GWAS) have provided considerable insight into the molecular control of…
Abstract Number: 1105 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled…
Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting
Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis
Mary Wallace¹, Rebecca Roberts², Payal Nanavati³, Jeffrey N Miner³, Nicola Dalbeth⁴, Ruth Topless⁵, Tony R. Merriman⁶ and Lisa K. Stamp⁷, ¹Surgical Sciences, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Ardea Biosciences, San Diego, CA, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁷University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Keith Petrie¹, Kate MacKrill¹, Christina Derksen² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Marburg, Marburg, Germany
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…
Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…
Abstract Number: 1109 • 2017 ACR/ARHP Annual Meeting
Sex Differences in Gout Patients: Epidemiology, Flares and Hospitalization Data in a Population Based Cohort
Mohanad Elfishawi^1,2,3, Clement J. Michet Jr.⁴, Cynthia S. Crowson⁵, Eric L. Matteson⁶ and Tim Bongartz⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, ³Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁷Emergency Medicine, Vanderbilt University, Nashville, TN
Background/Purpose: While gout is the most common form of inflammatory arthritis, there are relatively few studies on the influence of sex with regard to disease…
Abstract Number: 1110 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack
Jung Sun Lee¹, Seokchan Hong², Oh Chan Kwon², Byeongzu Ghang², Wook Jang Seo³, Doo-Ho Lim⁴, Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Seoul Veterans Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: To investigate the clinical features and risk of gout recurrence in patients with normouricemia during an acute attack Methods: This study was conducted in…
Abstract Number: 1111 • 2017 ACR/ARHP Annual Meeting
Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Yuqing Zhang^3,4 and Tuhina Neogi⁴, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: There is increasing evidence that allopurinol may be protective of kidney function among hyperuricemic subjects, though clinicians are often cautious about using allopurinol in…
Abstract Number: 1112 • 2017 ACR/ARHP Annual Meeting
Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Rochella A. Ostrowski¹, Elizabeth Araujo², Richard Hariman³ and Elaine Adams⁴, ¹Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ²Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Rheumatology, Edward Hines Jr Hospital, Veterans Administration, Hines, IL
Background/Purpose: Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration. No studies have evaluated the ideal dose…
Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Seoyoung C. Kim¹, Tuhina Neogi², Eun Ha Kang³, Jun Liu⁴, Rishi J. Desai⁵, MaryAnn Zhang⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Ying-Chou Chen Sr.¹, Shih-Chueh Chen², Chung-Tei Chou³, Carl Brown⁴, Jing-Yi Lee⁴, Wei-Shu Lu⁵ and Chang Youh Tsai⁶, ¹Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, ²Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, ³Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, ⁵TWi Biotechnology, Inc., Taipei, Taiwan, ⁶Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…
Abstract Number: 1115 • 2017 ACR/ARHP Annual Meeting
Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients
Fernando Perez-Ruiz¹ and Sandra Chinchilla², ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Barakaldo, Spain
Background/Purpose: adherence to urate-lowering treatment (ULT) in patients with gout is reported to be lower than 50% in the first year and below 20% at…
Abstract Number: 1116 • 2017 ACR/ARHP Annual Meeting
Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction
Dawen Zhang¹, Kichul Ko², Michael A. Becker² and Reem Jan¹, ¹Medicine, Rheumatology, University of Chicago, Chicago, IL, ²Medicine, University of Chicago, Chicago, IL
Background/Purpose: Patients with gout frequently have multiple serious co-morbidities, take concomitant medications, and have complex clinical profiles, making treatment of acute flares in hospital settings…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].